Gene · 5689
PSMB1: proteasome 20S subunit beta 1
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. PSMB1: proteasome 20S subunit beta 1. Genes, record 5689. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5689
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P20618 | Proteasome subunit beta type-1 | 241 | 176 | Ensembl, GeneID, HGNC |
Source UniProt
Patents18
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 59527 | P20618 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 2031 | P20618 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 2031 | P20618 | Espacenet |
| WO 2024240908 A1 | 2024-11-28 | 6 | P20618 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 67900 | P20618 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 170871 | P20618 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 9063 | P20618 | Espacenet |
| JP 2019054813 A | 2019-04-11 | 239962 | P20618 | Espacenet |
| JP 2017121241 A | 2017-07-13 | 239962 | P20618 | Espacenet |
| JP 2015516143 A | 2015-06-08 | 239962 | P20618 | Espacenet |
1 to 10 of 18
See all 18 patentsDrugs7
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| BORTEZOMIB | CHEMBL325041 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| BORTEZOMIB D-MANNITOL | CHEMBL5315122 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| CARFILZOMIB | CHEMBL451887 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| IXAZOMIB | CHEMBL2141296 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| IXAZOMIB CITRATE | CHEMBL3545432 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| MARIZOMIB | CHEMBL371405 | 20S proteasome inhibitor | INHIBITOR | ChEMBL |
| OPROZOMIB | CHEMBL2103884 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
Trials1,241
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07605416 | CARFILZOMIB | PHASE2 | ClinicalTrials.gov | |
| NCT07601100 | BORTEZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07600151 | BORTEZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07513129 | BORTEZOMIB | PHASE1 | ClinicalTrials.gov | |
| NCT07479979 | CARFILZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07464210 | BORTEZOMIB | PHASE2 | ClinicalTrials.gov | |
| NCT07463807 | CARFILZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07428369 | BORTEZOMIB | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07391657 | BORTEZOMIB | PHASE3 | ClinicalTrials.gov | |
| NCT07391657 | CARFILZOMIB | PHASE3 | ClinicalTrials.gov |
1 to 10 of 1,241
See all 1,241 trialsNIH grants651
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | PSMB1 papers | Newest fiscal year |
|---|---|---|---|
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 6 | 2025 |
| ZIAAI000904 | Staphylococcal pathogenesis | 5 | 2025 |
| ZIAAI001080 | Role of the human microbiota and probiotics | 3 | 2025 |
| P01AI169768 | High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir | 2 | 2025 |
| P01CA120964 | Molecular Pathogenesis of the Hamartoma Syndromes | 2 | 2025 |
| P30AI027763 | UCSF-Bay Area Center for AIDS Research | 2 | 2025 |
| P30AI060354 | Harvard University Center for AIDS Research | 2 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 2 | 2025 |
| P30CA015083 | Mayo Clinic Comprehensive Cancer Center Support Grant | 2 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 2 | 2025 |
1 to 10 of 651Source NIH's project files
See all 651 nih grantsPapers738
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Single-Cell-Derived Malignant Epithelial Programs Define Prognostic Risk and Therapeutic Vulnerability in Ovarian Cancer. | J Cancer | 2026 | 42524312 | PubTator, text mining | PubMed |
| PSMB1 screened by CRISPR-CAS9 promoted breast cancer progression via PI3K-AKT-mTOR signaling. | Discov Oncol | 2026 | 42177737 | PubTator, text mining | PubMed |
| 5-Hydroxymethylcytosine profiles in circulating cell-free DNA serve as potential biomarkers for diagnosis and classification of adenomyosis. | EBioMedicine | 2026 | 41861514 | PubTator, text mining | PubMed |
| Identifying prioritization of potential targets for idiopathic pulmonary fibrosis: Proteome-wide Mendelian randomization and colocalization analyses. | Clinics (Sao Paulo) | 2026 | 41855608 | PubTator, text mining | PubMed |
| Autophagy regulation and viral exploitation: insights into African swine fever virus pathogenesis. | Front Cell Infect Microbiol | 2026 | 41778015 | PubTator, text mining | PubMed |
| Multi-omics SMR and experimental supportive analyses decipher causal drivers hepatocellular carcinoma. | BMC Cancer | 2026 | 41699549 | PubTator, text mining | PubMed |
| Proteomics Reveals Differential Diagnosis Biomarkers Between Sepsis and Hemophagocytic Syndrome. | Biomedicines | 2025 | 41463121 | PubTator, text mining | PubMed |
| Clinical characteristics and whole-genome analysis of methicillin-resistant Staphylococcus aureus in ICU patients from a tertiary hospital in southern China. | Int J Med Microbiol | 2025 | 41289896 | PubTator, text mining | PubMed |
| Enhanced microbiological evaluation of brain abscesses by proteomics-based techniques: a prospective cohort study. | Neurosurg Focus | 2025 | 41175401 | PubTator, text mining | PubMed |
| Prediction of Immunotherapy Response and Prognostic Outcomes for Patients With Ovarian Cancer Using PANoptosis-Related Genes. | Hum Mutat | 2025 | 41141246 | PubTator, text mining | PubMed |
1 to 10 of 738
See all 738 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/5689
GET https://conductscience.org/api/genes/v1/5689/patents